No evidence of overweight in long-term survivors of childhood cancer after glucocorticoid treatment.

Détails

Ressource 1Télécharger: BIB_4C3CF398F3C2.pdf (469.03 [Ko])
Etat: Public
Version: Author's accepted manuscript
Licence: Non spécifiée
ID Serval
serval:BIB_4C3CF398F3C2
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
No evidence of overweight in long-term survivors of childhood cancer after glucocorticoid treatment.
Périodique
Cancer
Auteur⸱e⸱s
Belle F.N., Kasteler R., Schindera C., Bochud M., Ammann R.A., von der Weid N.X., Kuehni C.E.
Collaborateur⸱rice⸱s
Swiss Pediatric Oncology Group (SPOG)
ISSN
1097-0142 (Electronic)
ISSN-L
0008-543X
Statut éditorial
Publié
Date de publication
01/09/2018
Peer-reviewed
Oui
Volume
124
Numéro
17
Pages
3576-3585
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Résumé
Glucocorticoids can lead to weight gain during cancer treatment, but to the authors' knowledge, little is known regarding their long-term effects in childhood cancer survivors (CCS).
As part of the Swiss Childhood Cancer Survivor Study, the authors sent a questionnaire to CCS aged <21 years at diagnosis who were residing in Switzerland, had survived ≥5 years, and were aged 15 to 45 years at the time of the survey. Cumulative doses of glucocorticoids were assessed from medical records and study protocols and body mass index was calculated from self-reported height and weight at the time of the survey. The authors compared the prevalence of overweight between CCS, their siblings, and the general population (Swiss Health Survey [SHS]) and investigated the association between overweight and treatment-related risk factors using multivariable logistic regression.
The study included 1936 CCS, 546 siblings, and 9591 SHS participants. The median age of the CCS at the time of the survey was 24 years (interquartile range, 20-31 years) and the median time since diagnosis was 17 years (interquartile range, 12-22 years). At the time of the survey, approximately 26% of CCS were overweight, a percentage that was comparable to that among siblings (24%) and the SHS participants (25%). The prevalence of overweight was 24% in CCS treated with glucocorticoids only (686 CCS), 37% in those treated with cranial radiotherapy (CRT) (127 CCS), and 49% in those who received treatment with both glucocorticoids and CRT (101 CCS) (P < .001). The authors found no evidence of a dose-response relationship between cumulative glucocorticoid doses and overweight and no evidence that CRT modified the effect of the cumulative glucocorticoid dose on overweight.
The results of the current study suggest that glucocorticoids used for the treatment of childhood cancer are not associated with long-term risk of overweight.
Mots-clé
Adolescent, Adult, Age of Onset, Body Mass Index, Cancer Survivors/statistics & numerical data, Child, Female, Glucocorticoids/therapeutic use, Humans, Male, Middle Aged, Neoplasms/drug therapy, Neoplasms/epidemiology, Overweight/chemically induced, Overweight/epidemiology, Prevalence, Surveys and Questionnaires, Switzerland/epidemiology, Young Adult, Europe, Swiss Childhood Cancer Registry, childhood cancer survivors, cranial radiotherapy (CRT), late effects, obesity, steroids
Pubmed
Web of science
Création de la notice
29/08/2018 15:23
Dernière modification de la notice
28/09/2019 6:08
Données d'usage